| Drug Name |
Sitagliptin phosphate |
| Drug ID |
BADD_D02030 |
| Description |
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[Label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[Label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006[L6061]. |
| Indications and Usage |
Sitagliptin is indicated for the management of glycemic control in type 2 diabetes mellitus along with diet and exercise[Label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
A10BH01 |
| DrugBank ID |
DB01261
|
| KEGG ID |
D06645; D12294
|
| MeSH ID |
D000068900
|
| PubChem ID |
6451150
|
| TTD Drug ID |
D0U2JP
|
| NDC Product Code |
48087-0078; 60312-0107; 60312-0109; 67317-0113; 12666-0013; 58175-0620; 50370-0026; 65344-0031; 60312-0108; 49711-1519; 66039-873; 67317-0114; 15894-0018; 66651-917; 67317-0056; 65727-078; 73309-144; 48087-0154; 67835-0022; 71796-010; 75945-020; 48087-0155; 50370-0027; 59651-231; 65015-766; 69037-0022; 82608-006 |
| UNII |
TS63EW8X6F
|
| Synonyms |
Sitagliptin Phosphate | Phosphate, Sitagliptin | Sitagliptin Phosphate Monohydrate | Monohydrate, Sitagliptin Phosphate | Phosphate Monohydrate, Sitagliptin | Sitagliptin Monophosphate Monohydrate | Monohydrate, Sitagliptin Monophosphate | Monophosphate Monohydrate, Sitagliptin | MK 0431 | 0431, MK | MK0431 | MK-0431 | Sitagliptin Phosphate Anhydrous | Anhydrous, Sitagliptin Phosphate | Phosphate Anhydrous, Sitagliptin | Sitagliptin | 4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine | Januvia |
